• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer

    1/3/23 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email

    MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership

    MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company's manufacturing, supply chain, procurement, quality, and regulatory functions. Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services.

    "We are happy to begin 2023 with the addition of Ricci Whitlow to the MIMEDX leadership team," stated Todd Newton, MIMEDX interim Chief Executive Officer. "The future of placental-based biomaterial products and innovation will increasingly migrate from the current Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P's) regulatory landscape to either the device or biologics regulatory pathways. We also see greater operational complexity in the future as requirements migrate from Good Tissue Practices (GTPs) to current Good Manufacturing Practices (cGMPs). As our growth goals depend on our ability to manage these changes, we identified the need for a talented and capable operational leader with a unique span of scientific, technology, process and people-leadership expertise. We believe Ricci is this leader."

    "I am excited to be joining the MIMEDX team during this important period in the Company's history," stated Ms. Whitlow. "With MIMEDX's portfolio of best-in-class products and its rich product pipeline, the opportunity for our products to help a variety of patients in a variety of ways is truly remarkable. MIMEDX's lifeblood begins with precious birth tissue and combines with decades of expertise and knowhow to make products that clinicians and a growing number of patients rely upon. I look forward to working with my colleagues here to grow our operations and tackle the large and growing market opportunities we have in front of us, both today and in the future."

    "This role is absolutely critical to our long-term success," continued Mr. Newton. "I look forward to working with Ricci to continue to bring products to market and fulfill our mission of leveraging our placental biologics technology to help address large and growing unmet needs in medicine."

    Prior to her role at Catalent, Ms. Whitlow's extensive career has included leadership roles at a number of MedTech companies, including Optinose, LifeCell, Kinetic Concepts and Johnson & Johnson. Ms. Whitlow received her B.S. in Industrial Engineering from Texas A&M University and her M.B.A. from the NYU/LSE/HEC TRIUM program.

    About MIMEDX

    MIMEDX is a pioneer and leader in placental biologics, developing and distributing placental tissue allografts to help address unmet clinical needs in multiple sectors of healthcare, including the Advanced Wound Care market as well as in surgical recovery settings. MIMEDX is also focused on advancing a promising late-stage pipeline opportunity targeted at decreasing pain and improving function for patients with knee osteoarthritis. Our products are derived from human placental tissues and processed using our proprietary methods, including the Company's own PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

    Contact:

    Matt Notarianni

    Investor Relations

    470-304-7291

    [email protected]



    Primary Logo

    Get the next $MDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

      SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/12/24 4:04:33 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MiMedx Group Inc

      SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/7/24 10:25:58 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

      SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/4/24 1:30:50 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

      MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 20255:15 p.m. PDTWebcast Link Investors interested in meeting with senior management at this event may contact their Bank of America representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wou

      5/6/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

      MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: "Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis." Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most comm

      5/5/25 8:30:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces First Quarter 2025 Operating and Financial Results

      Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

      4/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Financials

    Live finance-specific insights

    See more
    • MIMEDX Announces First Quarter 2025 Operating and Financial Results

      Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

      4/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30

      MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13752696 A replay of the webcast will be available for approximately 30 days on the Company's

      4/16/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

      Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales

      2/26/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MiMedx Group Inc

      DEF 14A - MIMEDX GROUP, INC. (0001376339) (Filer)

      4/30/25 4:06:36 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MiMedx Group Inc

      10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)

      4/30/25 4:00:52 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

      4/30/25 4:00:21 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    See more

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

      Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

      7/17/24 8:00:00 AM ET
      $MDXG
      $SAVA
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

      MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

      6/26/24 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Appointment of Two New Independent Directors

      MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

      3/4/24 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 8,876 shares, decreasing direct ownership by 2% to 422,426 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      4/25/25 6:03:03 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 8,876 shares, decreasing direct ownership by 2% to 431,302 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      4/10/25 6:01:37 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      11/22/23 5:01:18 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

      Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

      7/2/24 7:38:13 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on MiMedx Group with a new price target

      Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      3/7/24 8:26:30 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on MiMedx Group with a new price target

      Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      10/27/23 9:04:53 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care